Герцептин: механизм действия


Цитировать

Полный текст

Аннотация

Герцептин (Herceptin, trastuzumab, трастузумаб) – первый таргетный препарат, разработанный для лечения опухолей эпителиального происхождения (раков) и внедренный в онкологическую практику более десяти лет назад. Таким образом, Герцептин является прототипом концепции таргетной терапии: история его создания и клинического применения прекрасно отражает весь комплекс возможностей, перспектив и ограничений, сопряженных с противоопухолевыми препаратами новой эры.

Об авторах

Е Н Имянитов

НИИ онкологии им. Н.Н.Петрова, Санкт-Петербург

Список литературы

  1. Ali I.U., Campbell G, Lidereau R, Callahan R. Amplification of c-erbB-2 and aggressive human breast tumors? Science 1988; 240 (4860): 1795–6.
  2. Allegra C.J., Jessup J.M., Somerfield M.R. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27 (12): 2091–6.
  3. Baselga J, Carbonell X, Castaneda-Soto N.J. et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23 (10): 2162–71.
  4. Beerli R.R., Wels W, Hynes N.E. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. Biol Chem 1994; 269 (39): 23931–6.
  5. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6 (4): 443–6.
  6. Cobleigh M.A., Vogel C.L., Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17 (9): 2639–48.
  7. Coussens L, Yang-Feng T.L., Liao Y.C. et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230 (4730): 1132–9.
  8. Force T, Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7 (5): 332–44.
  9. Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003; 4 (2): 120–5.
  10. Gelmon K.A., Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004; 5 (1): 52–62.
  11. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10 (17): 5650–5.
  12. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19 (9): 1523–9.
  13. Guarneri V, Frassoldati A, Bruzzi P et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 2008; 8 (5): 453–6.
  14. Hudis C.A. Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 2007; 357 (1): 39–51.
  15. Imyanitov E.N., Chernitsa O.I., Serova O.M., Knyazev P.G. Rare occurrence of amplification of HER-2 (erbB-2/neu) oncogene in ovarian cancer patients. Eur J Cancer 1992; 28A (6–7): 1300.
  16. Imyanitov E.N., Chernitsa O.I., Serova O.M. et al. Amplification of HER - 2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Neoplasma 1993; 40 (1): 35–9.
  17. Joensuu H, Kellokumpu-Lehtinen P.L., Bono P et al. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354 (8): 809–20.
  18. Kawaguchi Y, Kono K, Mimura K et al. Cetuximab induce antibodydependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120 (4): 781–7.
  19. Krug L.M., Miller V.A., Patel J et al. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer 2005; 104 (10): 2149–55.
  20. Lewis G.D., Figari I, Fendly B et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37 (4): 255–63.
  21. Nahta R, Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8 (6): 215.
  22. Nielsen D.L., Andersson M, Kamby C. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009; 35 (2): 121–36.
  23. Repka T, Chiorean E.G., Gay J et al. Trastuzumab and interleukin-2 in HER2 - positive metastatic breast cancer: a pilot study. Clin Cancer Res 2003; 9 (7): 2440–6.
  24. Romond E.H., Perez E.A., Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673–84.
  25. Sauter G, Lee J, Bartlett J.M. et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27 (8): 1323–33. Scandinavian Breast Group Trial 9401,
  26. Tanner M, Isola J, Wiklund T et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose - escalated anthracycline - based adjuvant chemotherapy in HER-2/neu - amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24 (16): 2428–36.
  27. Schechter A.L., Stern D.F., Vaidyanathan L et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312 (5994): 513–6.
  28. Semba K, Kamata N, Toyoshima K, Yamamoto T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor - receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 1985; 82 (19): 6497–501.
  29. Slamon D.J., Clark G.M., Wong S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 (4785): 177–82.
  30. Slamon D.J., Clark G.M. Amplification of c-erbB-2 and aggressive human breast tumors? Science 1988; 240 (4860): 1796–8.
  31. Slamon D.J., Godolphin W, Jones L.A. et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244 (4905): 707–12.
  32. Slamon D.J., Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783–92.
  33. Tripathy D, Slamon D.J., Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22 (6): 1063–70.
  34. Umemura S, Osamura R.Y., Akiyama F et al. What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard. Am J Clin Pathol 2008; 130 (6): 883–91.
  35. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18 (6): 977–84.
  36. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first - line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27: 18s, 2009 (suppl: ASCO Meeting Abstracts, Jun 2009), abstr LBA4509.
  37. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 2009; 27 (12): 1999–2006.
  38. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res 2008; 68 (9): 3077–80.
  39. Wolmark N, Yothers G, O'Connell M.J. et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08 J Clin Oncol 27: 18s, 2009 (suppl: ASCO Meeting Abstracts, Jun 2009; abstr LBA4.
  40. Zhou D, Battifora H, Yokota J et al. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res 1987; 47 (22): 6123–5.

© ООО "Консилиум Медикум", 2009

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial 4.0 International License.
 


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах